1001
Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma
Friday, March 4, 2016: 7:00 AM-9:30 AM
Convention Center, Level One, Petree Hall C
2.50 CME/CE
Course
Moderator:
Alkis Togias , MD FAAAAI

Learning Objectives:
  1. Discuss current and future approaches to allergen immunotherapy for asthma and allergic rhinitis
  2. Discuss the potential mechanisms by which immunotherapy modulates the immune response to allergens
  3. Discuss the durability of immune unresponsiveness induced by allergen immunotherapy
7:00 AM
T Cell Epitope Changes During Allergen Immunotherapy and Allergen Exposure
Alessandro Sette, Dr. Biol. Sci.
7:25 AM
A Unique T Cell Subset (TH2A) in Allergen Immunotherapy
Erik R. Wambre, PhD MBE
7:50 AM
Peptide Immunotherapy in Allergic Rhinoconjunctivitis and Asthma
Mark Larché, PhD
Handouts
  • LARCHE Handout AAAAI 2016.pdf (86.7 kB)
  • 8:15 AM
    Sublingual vs. Subcutaneous Immunotherapy: Which is More Potent?: The GRASS Trial
    Stephen R. Durham, MA MD FRCP
    8:55 AM
    How Can the Risk of Systemic Reactions to Subcutaneous Allergen Immunotherapy be Mitigated?
    Tolly Epstein, MD MS FAAAAI
    Handouts
  • 1001 course Epstein.pdf (559.2 kB)
  • 9:10 AM
    General Discussion
    See more of: Session